Marie Cullberg
- The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPDBy Anne Marie Kirsten, Karin Förster, Eva Radeczky, Anneliese Linnhoff, Beatrix Balint, Henrik Watz, Heather Wray, Lynette Salkeld, Marie Cullberg, Hung Lam and Bengt LarssonAnne Marie Kirsten1Pulmonary Research Institute, Hospital Grosshansdorf, GermanyKarin Förster2Practice for Pneumology and Cardiology, Practice for Pneumology and Cardiology, Berlin, GermanyEva Radeczky3MEN CARE Medical Centre, MEN CARE Medical Centre, Százhalombatta, HungaryAnneliese Linnhoff4Practice for Lung, Bronchial, Allergy and Environmental Medicine, Practice for Lung, Bronchial, Allergy and Environmental Medicine, GermanyBeatrix Balint5Chest Diseases Hospital, Deszk, HungaryHenrik Watz1Pulmonary Research Institute, Hospital Grosshansdorf, GermanyHeather Wray6Research & Development, AstraZeneca, Mölndal, SwedenLynette Salkeld6Research & Development, AstraZeneca, Mölndal, SwedenMarie Cullberg6Research & Development, AstraZeneca, Mölndal, SwedenHung Lam7Research & Development, AstraZeneca, Södertälje, SwedenBengt Larsson6Research & Development, AstraZeneca, Mölndal, Sweden
- The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteersBy Ulrike Lorch, Hedigo Negi, Hirobumi Tabata, Heather Wray, Marie Cullberg and Bengt LarssonUlrike Lorch1Richmond Pharmacology, St. George's University, London, United KingdomHedigo Negi2Research & Development, AstraZeneca K.K., Osaka, JapanHirobumi Tabata2Research & Development, AstraZeneca K.K., Osaka, JapanHeather Wray3Research & Development, AstraZeneca, Mölndal, SwedenMarie Cullberg3Research & Development, AstraZeneca, Mölndal, SwedenBengt Larsson3Research & Development, AstraZeneca, Mölndal, Sweden
- The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteersBy Tim Mant, Heather Wray, Marie Cullberg and Bengt LarssonTim Mant1Quintiles Drug Research Unit, Guy's Hospital, London, United KingdomHeather Wray2Research & Development, AstraZeneca, Mölndal, SwedenMarie Cullberg2Research & Development, AstraZeneca, Mölndal, SwedenBengt Larsson2Research & Development, AstraZeneca, Mölndal, Sweden
- Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonistBy Marie Cullberg, Heather Wray and Bengt LarssonMarie Cullberg1Research and Development, Innovative Medicines, AstraZeneca R&D, Mölndal, SwedenHeather Wray1Research and Development, Innovative Medicines, AstraZeneca R&D, Mölndal, SwedenBengt Larsson1Research and Development, Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.